Granisol

Chemotherapy, Operative Surgery, Nausea + 1 more

Treatment

3 FDA approvals

20 Active Studies for Granisol

What is Granisol

Granisetron

The Generic name of this drug

Treatment Summary

Ondansetron is a medication used to prevent nausea and vomiting caused by chemotherapy. It works by blocking serotonin receptors in the body, helping to reduce the feeling of nausea.

Kytril

is the brand name

Granisol Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Kytril

Granisetron

1993

63

Approved as Treatment by the FDA

Granisetron, also known as Kytril, is approved by the FDA for 3 uses such as Nausea and vomiting and Nausea .

Nausea and vomiting

Nausea

Chemotherapy

Effectiveness

How Granisol Affects Patients

Granisetron is a drug that blocks serotonin type 3 (5-HT<sub>3</sub>) receptors. It does not have any effect on other serotonin receptors, or on other types of receptors. In studies, it has not impacted blood pressure, heart rate, or ECG readings. This drug is similar to ondansetron, which also blocks 5-HT<sub>3</sub> receptors. When certain drugs are taken, they release serotonin from cells in the small intestine. This serotonin then stimulates nerve receptors in the brain, which can cause nausea and vomiting. Granisetron works by blocking these

How Granisol works in the body

Granisetron stops the vomiting center in your brain from being stimulated. It does this by blocking certain receptors that are found in the vomiting center and in your gastrointestinal tract. This stops signals from your body to the vomiting center that would normally cause you to vomit.

When to interrupt dosage

The recommended dosage of Granisol is contingent upon the diagnosed condition, such as Nausea, Radiation Therapy and Operative Surgery. The amount of dosage is contingent upon the technique of administration (e.g. Solution - Oral or Injection, solution) as recorded in the following table.

Condition

Dosage

Administration

Operative Surgery

, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL

, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Transdermal, Patch, Patch - Transdermal, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Subcutaneous, Injection - Subcutaneous, Solution - Oral

Radiation Therapy

, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL

, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Transdermal, Patch, Patch - Transdermal, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Subcutaneous, Injection - Subcutaneous, Solution - Oral

Chemotherapy

, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL

, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Transdermal, Patch, Patch - Transdermal, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Subcutaneous, Injection - Subcutaneous, Solution - Oral

Nausea

, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL

, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Transdermal, Patch, Patch - Transdermal, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Subcutaneous, Injection - Subcutaneous, Solution - Oral

Warnings

There are 20 known major drug interactions with Granisol.

Common Granisol Drug Interactions

Drug Name

Risk Level

Description

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Granisetron is combined with Anagrelide.

Apomorphine

Major

The risk or severity of hypotension can be increased when Granisetron is combined with Apomorphine.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Granisetron is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Granisetron is combined with Artemether.

Asenapine

Major

The risk or severity of QTc prolongation can be increased when Granisetron is combined with Asenapine.

Granisol Toxicity & Overdose Risk

The lowest toxic dose of the drug in rats has been found to be greater than 2000mg/kg when taken orally.

Granisol Novel Uses: Which Conditions Have a Clinical Trial Featuring Granisol?

85 active clinical trials are currently underway to ascertain the efficacy of Granisol in alleviating Nausea, Operative Surgery and Radiation Therapy.

Condition

Clinical Trials

Trial Phases

Operative Surgery

71 Actively Recruiting

Phase 3, Not Applicable, Phase 4, Phase 1, Phase 2, Early Phase 1

Radiation Therapy

6 Actively Recruiting

Not Applicable, Phase 3, Early Phase 1

Nausea

0 Actively Recruiting

Chemotherapy

4 Actively Recruiting

Phase 1, Phase 3, Not Applicable

Patient Q&A Section about granisol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Granisol

Image of Washington University / Barnes Jewish Hospital in St Louis, United States.

AI-Driven Clinical Decision Support for Surgery

18+
All Sexes
St Louis, MO

20 million patients have surgery in the United States every year, with approximately 1 million of those patients requiring life-saving blood transfusion. Presurgical preparation for transfusion is important to allow for safe and timely transfusion during surgery; however, excessive preparation is unfortunately common, costly, and contributes to blood waste. This study aims to evaluate an intelligent clinical decision support system that helps clinicians prepare blood for patients who are likely to need it, while avoiding excessive preparation for patients who don't, potentially improving patient safety while reducing blood waste and healthcare costs.

Recruiting
Has No Placebo

Washington University / Barnes Jewish Hospital

Image of UPMC Hillman Cancer Center in Pittsburgh, United States.

Mobile App for Cancer

18+
All Sexes
Pittsburgh, PA

The goal of this study is to determine whether a mobile application that combines real-time sensor data and patient-reported symptoms to trigger care-team contact recommendations is feasible and beneficial for patients receiving chemotherapy. The main questions it aims to answer are: * Is the mobile application feasible and acceptable to patients? * Do the alerts and guidance improve symptom management, quality of life, and engagement with the care team during treatment? Participants will: * Complete a demographic questionnaire at the beginning of the study and quality-of-life and health questionnaires at the beginning, midpoint, and end of study. * Complete daily symptom ratings via study application. * Wear a Fitbit activity tracker for 90 days. * At the end of the study, complete a semi-structured interview to provide feedback on the study. * Optional: At the beginning and end of the study, complete an in-person physical function assessment measuring balance (Short Physical Performance Battery).

Waitlist Available
Has No Placebo

UPMC Hillman Cancer Center

Carissa A Low

Have you considered Granisol clinical trials?

We made a collection of clinical trials featuring Granisol, we think they might fit your search criteria.
Go to Trials
Image of Walter Reed National Military Medical Center in Bethesda, United States.

Corticosteroid Injections for Osteoarthritis

18+
All Sexes
Bethesda, MD

The goal of this clinical trial is to find out which type of steroid medicine, when added to a standard pain-control injection during total knee replacement surgery, works best at reducing pain, limiting opioid use, and improving recovery in adults undergoing surgery for severe knee arthritis or injury. The main questions it aims to answer are: Does adding a steroid to the injection improve pain control and reduce opioid use after surgery? Is the newer extended-release steroid (Zilretta) more effective and safer-especially for patients with diabetes-than the traditional steroid (methylprednisolone)? Researchers will compare: Standard pain-control injection alone Standard injection plus methylprednisolone Standard injection plus Zilretta to see which option provides better pain relief, less opioid use, and improved knee function. (Patients with diabetes or prediabetes will only be in the standard injection or Zilretta groups so researchers can study whether Zilretta is safer for blood sugar control.) Participants will: Be randomly assigned to one of the study groups during their total knee replacement surgery Receive the assigned pain-control injection around the knee joint Be followed after surgery to measure: Pain levels Opioid pain medication use Knee movement (range of motion) Whether another procedure (such as manipulation under anesthesia) is needed if the knee becomes too stiff Patient-reported outcome surveys about pain and function

Phase 2 & 3
Waitlist Available

Walter Reed National Military Medical Center

John P Cody, MD

Have you considered Granisol clinical trials?

We made a collection of clinical trials featuring Granisol, we think they might fit your search criteria.
Go to Trials
Image of Nationwide Children's Hospital in Columbus, United States.

Surface Electromyography for Surgery

No minimum age - 21
All Sexes
Columbus, OH

The investigators are studying a type of technology that is already used called surface electromyography (EMG). This measures and records electrical activity using sensor stickers in a non-invasive way. The purpose of this study is to use a prototype/test surface EMG machine to measure how well regional anesthesia (nerve block) is working. This device is non-invasive and being used for research use as an unapproved medical device. The information may teach us how to give nerve blocks more safely and effectively. Study participation: Subjects having surgery will have the surface EMG sensor stickers placed on their arms or legs before surgery. These will stay on during surgery and for part of recovery. Study visits: The study will consist of 1 visit that starts in the pre-operative area, through the surgery, and for part of recovery time after surgery.

Waitlist Available
Has No Placebo

Nationwide Children's Hospital

Grant Heydinger, MD

Image of UC Davis Dermatology in Sacramento, United States.

Ethyl Chloride Spray for Pain Reduction in Surgery

18+
All Sexes
Sacramento, CA

Fear of needles is a well-documented issue that affects many patients. This fear may cause significant anxiety in various medical situations, including in the dermatology office 1. If not properly managed, needle phobia can persist, affecting a patient's experience during each visit. This effect may compound and lead to avoidance behaviors that can delay necessary treatments 2. This issue is particularly relevant in a Mohs micrographic surgery (MMS) clinic where each patient experiences several painful needle injections before the day is over. Ethyl chloride is gaining popularity among dermatologists for its routine use in clinical practice due to its anesthetic and antiseptic properties, especially as a pre-injection agent. Research indicates that cryotherapy or pre-cooling the skin before administering a local anesthetic may offer benefits over topical anesthetics, such as enhanced pain relief, quicker onset, and better patient compliance 3,4. However, to our knowledge, no studies have specifically examined the effectiveness of pre-cooling with ethyl chloride prior to Mohs micrographic surgery. To address this gap, we're conducting a trial aimed at evaluating the impact of pre-cooling with ethyl chloride on pain perception in adult patients undergoing Mohs micrographic surgery with local anesthetic injections. The trial is a single-center, split-body study. The split-body design will involve dividing the surgical site into two equal halves, with one half (right side relative to patient) designated as the treatment side (receiving ethyl chloride spray prior to lidocaine injection) and the other as the control side (no ethyl chloride spray prior to injection). During the procedure, the participant will be asked to rate the pain associated with the needle injection AND the pain from infiltration of anesthetic from each side of the wound using the visual analog scale (VAS) scoring system (1 = no pain, 10 = most amount of pain possible). The results of the study will help us better understand how to mitigate pain and anxiety for patients requiring MMS.

Phase < 1
Recruiting

UC Davis Dermatology

Image of CHU de Québec-Université Laval (Hôpital de l'Enfant-Jésus) in Québec, Canada.

Lidocaine + Dexmedetomidine for Surgery Outcomes

18+
All Sexes
Québec, Canada

Up to 40% of patients experience suboptimal recovery in the days following major surgery, limiting their return to functional independence. Few preventive interventions exist, but intravenous dexmedetomidine and lidocaine administered during general anesthesia represent simple strategies that may significantly impact recovery and other patient-centred outcomes after surgery. The goal of this pilot trial is to determine the feasibility of conducting a phase 3 pragmatic adaptive multicentre trial to evaluate the impact of dexmedetomidine and lidocaine administered during major non-cardiac surgery on patient-centred outcomes.

Recruiting
Has No Placebo

CHU de Québec-Université Laval (Hôpital de l'Enfant-Jésus)

Michael Verret, MD PhD FRCPC

Have you considered Granisol clinical trials?

We made a collection of clinical trials featuring Granisol, we think they might fit your search criteria.
Go to Trials